IL287280A - Compounds and methods for the treatment of ocular disorders - Google Patents

Compounds and methods for the treatment of ocular disorders

Info

Publication number
IL287280A
IL287280A IL287280A IL28728021A IL287280A IL 287280 A IL287280 A IL 287280A IL 287280 A IL287280 A IL 287280A IL 28728021 A IL28728021 A IL 28728021A IL 287280 A IL287280 A IL 287280A
Authority
IL
Israel
Prior art keywords
compounds
treatment
methods
ocular disorders
ocular
Prior art date
Application number
IL287280A
Other languages
English (en)
Hebrew (he)
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of IL287280A publication Critical patent/IL287280A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL287280A 2019-04-18 2021-10-14 Compounds and methods for the treatment of ocular disorders IL287280A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US202062966482P 2020-01-27 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
IL287280A true IL287280A (en) 2021-12-01

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287280A IL287280A (en) 2019-04-18 2021-10-14 Compounds and methods for the treatment of ocular disorders

Country Status (9)

Country Link
US (2) US11643429B2 (https=)
EP (1) EP3955937A4 (https=)
JP (1) JP2022529315A (https=)
KR (1) KR20210154214A (https=)
CN (1) CN114007625A (https=)
AU (1) AU2020259997B2 (https=)
CA (1) CA3136369A1 (https=)
IL (1) IL287280A (https=)
WO (1) WO2020212760A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP7700045B2 (ja) 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
IL302173A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
EP4419502A4 (en) * 2021-10-20 2025-10-29 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
WO2024134266A1 (en) * 2022-12-20 2024-06-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
RU2263117C2 (ru) * 2001-04-27 2005-10-27 Пфайзер Продактс Инк. Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310962D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
GB0310980D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
WO2010086350A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9-deoxo- 9a-methyl- 9a- aza- 9a-h0m0erythr0mycin a derivatives for the treatment of neutrophil dominated inflammatory diseases
WO2011100769A2 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer
CA2840626A1 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
AU2013239679A1 (en) * 2012-03-27 2014-10-30 Michael W. BURNET Anti-inflammatory macrolides
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
JP2019513775A (ja) 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
EP3600272A4 (en) 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES

Also Published As

Publication number Publication date
EP3955937A4 (en) 2023-01-18
JP2022529315A (ja) 2022-06-21
WO2020212760A2 (en) 2020-10-22
KR20210154214A (ko) 2021-12-20
AU2020259997B2 (en) 2025-08-07
AU2020259997A1 (en) 2021-11-25
CA3136369A1 (en) 2020-10-22
US20230348517A1 (en) 2023-11-02
US11643429B2 (en) 2023-05-09
US20210230205A1 (en) 2021-07-29
WO2020212760A3 (en) 2021-02-25
CN114007625A (zh) 2022-02-01
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
IL287280A (en) Compounds and methods for the treatment of ocular disorders
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
IL287264A (en) Compounds and methods for the treatment of ocular disorders
IL267818A (en) Methods for treating neurological disorders
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
SG11202100092QA (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
EP3661502A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
IL279634A (en) Preparations and methods for the treatment and prevention of neurological disorders
PL3603621T3 (pl) Liposomy do leczenia chorób oczu
EP4010347A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN AND ADDICTION DISORDERS
EP3644966A4 (en) TREATMENT AND DIAGNOSIS OF EYE SURFACE DISORDERS
IL289221A (en) Compounds for the treatment of vision disorders
IL269400A (en) Medicines and preparations for the treatment of eye disorders
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
EP4232458A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
IL288234A (en) Compounds for the treatment of neuromuscular disorders
IL280588A (en) Ophthalmic compositions and methods for treating eye problems and skin diseases
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40074660A (en) Methods for the treatment of apoc3-related diseases and disorders
HK40084516A (en) Compounds and methods for the treatment of eye disorders
AU2020901858A0 (en) Compounds and Methods for the Treatment of Eye Disorders
AU2020901856A0 (en) Compounds and Methods for the Treatment of Eye Disorders